Vistagen Therapeutics, Inc.

VTGN

Explore Our Financial Data > Companies > California Companies > Vistagen Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	VTGN
CIK	0001411685
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Website	vistagen.com
Phone	650-577-3600
CEO	Shawn K. Singh
Employees	40

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$646,000.00
Pre-Tax Income	$-55.77 million
Net Income	$-55.78 million
Net Income to Common	$-55.78 million
EPS	$-1.75

View All

Balance Sheet

Cash	$48.98 million
Assets	$68.92 million
Liabilities	$12.16 million
Common Equity	$56.76 million
Liabilities & Equity	$68.92 million

View All

Cash Flow Statement

Net Income	$-55.78 million
Cash From Operating Activities	$-50.07 million
Cash From Investing Activities	$-8.47 million
Cash From Financing Activities	$4.61 million
Change in Cash	$-53.93 million

View All

Calculations

NOPAT	$-41.75 million
EBITDA	$-58.99 million
Price to Earnings	N/A
Price to Book	$1.71
ROE	-69.05%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

While institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the most

Key Insights Significant control over Vistagen Therapeutics by retail investors implies that the general public has...

Article Link

Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...

Vistagen Therapeutics Inc (VTGN) progresses its lead candidate for social anxiety disorder while navigating increased R&D expenses and competitive pressures.

Article Link

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif., August 07, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update.

Article Link

Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link